Apply for Office
Geoffrey J. Hasemer, Chief Executive Officer
The CEO of Genomic Health, Inc., speaks of the future of breast cancer:
A major step toward individualized treatment, and to end overtreatment
Today, one in 12 Japanese women develop breast cancer, and its incidence rate is increasing annually. According to the National Cancer Center of Japan, the five-year survival rate for breast cancer patients is over 90%. While breast cancer is seen as a relatively easy to cure cancer, the five-year survival rate drops to around 30% in its advanced state.
In reality, there are various types of breast cancer, and effective therapies exist for each. However, this also means that, with the wrong diagnosis, a cancer may not be treated with treatment method that is most effective for it.
The Oncotype DX® breast cancer test was developed to solve this problem. With this test, 21 kinds of genes are analyzed to predict the probability of breast cancer recurrence within the next 10-year period. The results are conveyed as a quantified score between 0 and 100, which is used as a basis for the selection of the “optimal treatment” for the patient.
Mr. Hasemer hails from Perth, Australia. After attending the University of Western Australia and Hitotsubashi University in Tokyo, he joined a company in Tokyo. He went to the United States in 1987 and received his MBA from Stanford University in 1989. After studying business in the San Francisco Bay area, with its large concentration of healthcare and IT venture companies, Mr. Hasemer worked for Pilkington Visioncare and, later, the Guidant Corporation. After returning to Japan, Mr. Hasemer served as a managing director at Cordis Cardiology Japan and at Johnson & Johnson (Medical) Japan, followed by his appointment as President of Abbott Vascular Japan K.K. He assumed his current position at Genomic Health, Inc. after serving as the operating officer and head of sales at Fuji Respironics under Philips (Netherlands).
Genomic Health was founded in 2000 in Redwood City, California. Its stated mission is to replace the one-size-fits-all approach to fighting cancer by promoting personalized care using the latent capabilities of the genetic revolution.
The Oncotype DX® Breast Recurrence Score test was launched in the United States market in 2004. This test was introduced to the Japanese and European markets in 2007.
We provide total business support through our Business Development Office, our Tokyo 21c Club of members from a wide range of industries and our highly experienced management team.